Cancer Research Technology
Log in Register
Menu

Anti-Phospho MDM2 (Ser186) [2G2 2.2]
RECENTLY UPDATED

Info

Catalogue Number 151309
Applications WB
Antigen/Gene or Protein Targets Murine Double Minute 2 protein (MDM2), Phosphorylated (Serine 186)
Reactivity Human
Relevance
RECENTLY UPDATED
Monoclonal antibody which targets the critical ser186 residue for MDM2 function.

Background and Research Application
MDM2 is a ubiquitin ligase whose principal function is the ubiquitination and degradation of p53 tumour suppressor protein. This promotes progression through the cell cycle and cell survival. MDM2 has been shown to negatively regulate p53 function. MDM2 binds and inhibits transactivation role played by p53 and overexpression of MDM2 can result in the inactivation of p53 and decrease its tumour suppressor function.

MDM2 is over-expressed in many tumours, including soft tissue carcinomas and breast cancer. The phosphorylation of serines 166 and 186 is necessary for MDM2's translocation into the nucleus, thereby facilitating interaction with p53. More than 40 different alternatively spliced transcript variants of MDM2 have been isolated from both tumour and normal tissues.

This antibody is directed against serine 186, which is crucial for MDM2 function.
Host Mouse
Immunogen Peptide QRKRHKS(p)DSIS. S(p) represent a phosphorylated serine. This peptide represents the portion of MDM2 around Serine 186
Immunogen UniProt ID
RECENTLY UPDATED
Q00987
Positive Control Breast carcinoma
Subclass IgG1
Molecular Weight (kDa) 90
Myeloma Used Sp2/0-Ag14
Recommended Growing Conditions DMEM + 5% FCS
Strain Balb/c
Notes
RECENTLY UPDATED
Production Details
Purified using multi-step affinity chromatography with protein A.

Storage Conditions
Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles.

Concentration
1mg/ml as standard
Research Area Cancer, Cell Cycle, Epigenetics & Nuclear Signalling

References

There are 2 reference entries for this reagent.

View All References

References: 2 entries

Wei et al. 2013. Oncogene. 32(9):1110-20. PMID: 22525275.

Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion.

Europe PMC ID: 22525275


Add a reference

References: 2 entries

Wei et al. 2013. Oncogene. 32(9):1110-20. PMID: 22525275.

Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion.


Add a reference

Inventor Information

No inventors are currently linked to this reagent.

Add an inventor